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Abstract: Simultaneous detection of several biological processes in vivo is 
a common requirement in biomedical and biological applications, and in 
order to address this issue the use of multiple fluorophores is usually the 
method of choice. Existing methodologies however, do not provide 
quantitative feedback of multiple fluorophore concentrations in small 
animals in vivo  when their spectra overlap, especially when imaging the 
whole body in 3D. Here we present an approach where a spectroscopic 
module has been implemented into a custom-built Fluorescence Molecular 
Tomography (FMT) system. In contrast with other multispectral 
approaches, this multimodal imaging system is capable of recording the 
fluorescence spectra from each  illumination point during a tomographic 
measurement. In situ spectral information can thus be extracted and used to 
improve the separation of overlapping signals associated with different 
fluorophores. The results of this new approach tested on both in vitro and in 
vivo  experiments are presented, proving that accurate recovery of 
fluorophore concentrations can be obtained from multispectral tomography 
data even in the presence of high autofluorescence. 
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(170.3880) Medical and biological imaging; (170.6960) Tomography; (170.6510) Spectroscopy, 
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1. Introduction 
In vivo optical imaging methods have seen an increase in applications following the recent 
expansion of commercially-available fluorescent agents [1–4]. Tomographic approaches such 
as Diffuse Optical Tomography (DOT) [5–8] and Fluorescence Molecular Tomography 
(FMT) increase the capabilities of optical imaging and offer many advantages including cost 
reduction, ease-of-use, molecular specificity, sensitivity and quantification accuracy [9–11]. 
Specifically, when FMT is combined with externally administrated fluorescent probes or 
transgenic animals expressing fluorescent proteins, a variety of different biological processes 
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potentially overlapping signals need to be imaged, where each signal corresponds to a specific 
process. Examples include immunologic studies of different T cell populations [17], viral gene 
delivery to diseased tissue e.g. cancer therapy [15], gene expression, cancer detection and 
therapeutic developments [18]. The multi-faceted aspect of these applications requires the use 
of unmixing techniques to extract each fluorescence signal independently, yet image them 
simultaneously. In fluorescence microscopy these techniques are commonly used in the form 
of linear spectral unmixing algorithms applied pixel-by-pixel in 2D images obtained in 
different spectral regions using interference filters [19–24] (standard  methods). However, 
when imaging in 3D, a 2D approach does not provide accurate results, neither qualitatively or 
quantitatively, as proven recently [25,26]. The highly heterogeneous nature of biological 
specimens present in small animals results in a wide distribution of optical properties and high 
inherent autofluorescence that demands tomographic approaches with spectral priors, in the 
form of emission spectra of the fluorophores (literature method), for improved reconstructions 
[27,28]. Optical heterogeneity in and between samples significantly reduces the applicability 
of standard unmixing methods in vivo even when applied in a volumetric fashion. 
In this work we present a new approach that combines FMT with spectroscopic analysis. 
The simultaneous and in situ  detection of spectral information during FMT acquisition 
provides localized tissue specificity when calculating the relative contributions of the 
investigated fluorophores, thus increasing the accuracy of in vivo quantification, even with 
overlapping emissions. In the results presented here the contribution of each fluorophore is 
calculated by fitting the spectra obtained during the FMT acquisition to a linear combination 
of the measured spectra of the isolated fluorophores. A linear unmixing algorithm is then 
applied, using these fitted values, to the reconstructed data in order to retrieve the unmixed 3D 
reconstructions. 
We have first assessed this methodology with phantom studies before applying it in more 
realistic in vivo proof-of-principle studies. Results obtained from the animal studies show that 
accurate quantification can be obtained from multi–spectral fluorescence tomography data, 
achieving a significant increase in quantification accuracy when compared to treating the raw 
data with the standard 2D unmixing approach with known spectra from a fluorimeter. 
This paper is organized as follows: In the following section the materials used as well as 
the experimental setup and the measurement procedures are explained in detail. Section 3 is 
dedicated to describing the method for spectral unmixing when in situ spectral measurements 
are employed to improve standard methods. In Section 4 the results obtained from phantom 
and in vivo studies are presented and discussed, while in Section 5 the conclusions of the 
study are presented. 
2. Materials and methods 
In order to test the combined Spectral/FMT setup the fluorophores chosen were CFSE 
(Carboxyfluorescein succinimidyl ester (CFDA(5(6) -CFDA SE), Invitrogen, Carlsbad, USA) 
with absorption maximum at 492nm and emission maximum at 517nm) and ATTO590 (Atto-
Tec, Germany), with absorption maximum at 594 nm and emission maximum at 624 nm. 
These fluorophores were chosen due to their common use in biological research as cell tracers 
and have significant overlapping spectra. Additionally, at these wavelengths tissue is known 
to present high autofluorescence levels, putting to test the unmixing approach in a realistic 
situation. 
The combined Spectral/FMT system for fluorescence and spectroscopy acquisitions is 
shown in Fig. 1 and is based on incorporating a spectroscopic module to our existing FMT 
imager (see Refs. [16,26] for details on the setup). The system used the 488nm and 514nm 
emission lines from an Argon ion laser as excitation sources and interference bandpass filters 
(Andover Corporation, USA), centred at 540nm  ±  20nm and 615nm  ± 45nm for isolating the 
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the excitation wavelengths is OD ≥ 5. 
The spectroscopic module consisted of a Czerny-Turner spectrograph (ANDOR 
Technologies, SR-163, 163mm focal length, numerical aperture f/3.6) to which a 16bit CCD 
camera (DV 434, ANDOR Technologies, Belfast, Northern Ireland) was attached to its output 
while light was guided to the entrance by means of an optical fiber. The collecting end of the 
fiber was located inside the imaging chamber, fixed to the sample platform and next to the 
objective lens covering the field of view of the CCD, which was wider than the scanning area 
and collecting spectra in reflection geometry. Wide field light collection from the surface of 
the subject and fiber coupling was performed with a lens (OFR CFC – 5 – VIS, Optics for 
Research, Newton, USA) attached to the fiber with FC/FC standard connections. A long pass 
filter (Schott OG-530, Edmund Optics, Barrington, USA) with an edge wavelength at 530 nm 
and an OD ≥  5 at the excitation wavelength was placed behind the entrance of the 
spectrograph to eliminate any laser light guided through the fiber. Synchronisation of FMT 
and spectral acquisitions was automated, thus recording one spectrum for each illumination 
point on the sample. Experiments were performed in reflection geometry on both tissue-like 
phantoms and on fluorescing implants in mice for a comparative in vivo study. 
 
Fig. 1. The Spectral/FMT experimental setup. R and T stand for the position of the mirror for 
Reflection or Transmission geometries. 
3. Spectral unmixing 
Spectral unmixing of fluorophore emission is based on the fact that the detected fluorescence 
signal can be expressed as a linear combination of the different fluorescent components 
present in the sample. When spectral contributions are calculated from in situ measurements 
as in the case of our system, light absorption at different wavelengths while travelling from 
the fluorophore to the detector can be taken into account. Hence, for each detection channel a 
linear equation can be derived that is comprised of the sum of the concentration of the 
fluorescence emitters multiplied by a weighting factor corresponding to the strength of the 
emission in that channel. If the number of detection channels is equal to the number of the 
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solved to calculate the unknown concentrations. 
 
Fig. 2. Characteristic spectra obtained with our Spectral/FMT system and the corresponding 
fittings for the calculation of the spectral contributions of the two fluorophores. (a) A schematic 
of the measurement geometry with the positions where the spectra were collected (solid stars) 
in respect to the position of the tubes (green for CFSE and red for ATTO590). (b) and (c) 
Spectra for 488nm and 514nm excitation respectively (green and red triangles) and the 
corresponding fittings (black squares). 
Spectra were collected for each illumination point through the spectrograph, and then data 
were plotted after calibration with a commercial Hg lamp (HG-1 Mercury Argon Calibration 
Source, OceanOptics, Dunedin, USA). As an example, Fig. 2 shows the spectra corresponding 
to two different illumination points (indicated by the solid stars in Fig. 2a) on the phantom 
containing the two fluorophores placed 3mm apart at a depth of 6mm. From these spectra the 
contribution of each fluorophore was calculated by fitting each acquired spectrum to the 
known spectra of CFSE and ATTO590 and obtaining the relative strengths for each spectral 
region as follows: 
  () () () () ii i i i i Ufit g G r R bkgrd λλ λλ = ++    (1) 
where Ufiti is the fitted spectrum, gi(λ) and ri(λ) are the fitted spectral contributions of the 
fluorophores for the excitation wavelength i as a function of wavelength λ and Gi(λ) and Ri(λ) 
are the known spectra of the fluorophore obtained independently. The parameter bkgrdi 
corresponds to any other spectral contribution such as non-specific autofluorescence, its initial 
value corresponds to the minimum value recorded and is effectively subtracted in each 
spectrum. The index i corresponds to the excitation wavelength. By means of a least squares 
algorithm the error parameter of Eq. (2) is minimized and the spectral contributions gi(λmin, 
λmax) and ri(λmin, λmax) over the detection bandpass region of the filters [λmin, λmax], are obtained 
as shown in Eqs. (3) and (4). Index x corresponds to the fluorophore, in our case CFSE and 
ATTO590. 
 
( )
2
ii
n
n
U Ufit
err
N
−
=
∑
   (2) 
where  Ui  is the in situ  recorded spectra, in the case of Fig. 2  the green and red spectra 
corresponding to the two excitation wavelengths. 
 
560 660
min max 488 488 min max 514 514
520 570
( , ) ( )   and  r ( , ) ( )
nm nm
CFSE CFSE
nm nm
g g Gd g Gd λλ λ λ λλ λ λ == ∫∫    (3) 
 
560 660
590 min max 488 488 590 min max 514 514
520 570
( , ) ( )   and  r ( , ) ( )
nm nm
ATTO ATTO
nm nm
g r Rd r Rd λλ λ λ λλ λ λ == ∫∫   (4) 
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the fluorophores (one for each excitation/filter pair). They were then used to unmix the 3D 
FMT reconstructions in order to retrieve the 3D unmixed images of each fluorophore’s 
concentration solving the following matrix equation for C which corresponds to the unknown 
3D concentrations of the fluorophores. 
  [ ] [] [ ] U sC = ×    (5) 
In the case of two fluorophores as in our study the fluorescence reconstructions in each 
detection channel will correspond to the following linear equations: 
 
590 590
590 590
g CFSE CFSE ATTO ATTO
r CFSE CFSE ATTO ATTO
UgC g C
UrC r C
= +
= +
   (6) 
where Ug, Ur are the fluorescence reconstructions in the detection channels for CFSE and 
ATTO590, gCFSE, gATTO590, rCFSE and rATTO590 are the spectral strengths of CFSE and ATTO590 
obtained as shown by Eqs. (3) and (4). CCFSE and CATTO590 are the unknown reconstructed 
fluorescence concentrations of each fluorophore. If the previous system is expressed in matrix 
notation we obtain: 
 
590
590 590
g CFSE CFSE ATTO
CFSE ATTO ATTO r
U C gg
rr C U
  
=×   
  
   (7) 
The solution of the system is given by the following equation that provides the unknown 
concentrations: 
 
1
590
590 590
g CFSE CFSE ATTO
CFSE ATTO ATTO r
U C gg
rr C U
−
  
=×  
  
   (8) 
The tomographic measurements were obtained by detecting the emission and the excitation 
images, using the normalized Born algorithm [29], and inverting the data with an Algebraic 
Reconstruction Technique (ART) with positive restriction for the reconstruction of the 3D 
fluorescence concentration [30]. Our method has been assessed both in reflection and 
transmission, described elsewhere [26], with very good results in both geometries. Here, 
however we present results only in reflection which is the geometry preferred for our in vivo 
studies where subcutaneous organs of the lymphatic system are imaged. 
4. Results 
The phantoms used in our experiments consisted of 20% Intralipid and black India ink both 
added to distilled water. The concentrations used were 5ml Intralipid and 4.88μl ink in a 
solution of 100ml total volume, in order to achieve an absorption coefficient of approximately 
μa = 0.3 cm
−1 and a reduced scattering coefficient of approximately μs' = 16 cm
−1, both being 
realistic  in vivo  values [31–33]. Fluorophores were added by using borosilicate micro 
capillary tubes (Drummond Scientific, US) with an outer diameter of 1.8 mm and an inner of 
1.2 mm embedded inside the phantom at a depth of 6mm. The in vitro measurements were 
performed by keeping the CFSE concentration constant at 4μM and varying the ATTO590 
concentration at 5μM, 10 μM and 15 μM. A pattern of 5x12 sources covering an area of 
5x18mm
2 was used. All measurements were performed in non-contact reflection geometry 
(see Ref. [16] and references therein). The same methodology though, could be applied also in 
transmission geometry as described previously [26]. 
The results are presented in Fig. 3 where the reconstructed concentrations were plotted 
against the true ones, when the unmixing is performed in one of two ways: calculating the 
spectral strengths by i) fitting the in situ collected spectra, represented by the open and solid 
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of the fluorophores obtained  independently, represented by the open and solid inverted 
triangles for CFSE and ATTO590 (literature). Both data were fitted to a linear regression 
model with R
2 = 0.9998 for case i and R
2 = 0.9988 for case ii. However, the recovered slope is 
correct only for case (i): slope(i) = 1.03 whereas slope(ii) = 0.759 demonstrating the higher 
accuracy of the measured  spectral fitting method (i).  Figure 3b  shows the ratios of the 
recovered concentrations of ATTO590 over CFSE for the measured and literature spectra 
(solid squares and open triangles, respectively) as well as the calculated known concentration 
ratios (solid circles), illustrating the improved accuracy that is achieved when measuring and 
fitting the spectra. The corresponding concentrations recovered using the unmixing on the 
original measurements (standard method) are also shown (open circles) demonstrating the 
inability of this method to correctly calculate the independent fluorescence concentrations 
[26]. Unmixed 3D reconstructed images are shown in Figs. 3c and 3d where signals from the 
two fluorophores are clearly separated. Phantom experiments are very valuable for evaluation 
of methods and algorithms, but cannot substitute more realistic in vivo studies. Hence, we 
evaluated our unmixing method with  fluorescing implants in mice as presented in the 
following paragraph. 
 
Fig. 3. (a) Quantification results from the phantom study for the recovered concentrations of 
ATTO590 and CFSE for the two methods of obtaining the spectral strengths (see text for 
details). (b) Ratios of the recovered concentrations of ATTO590 over CFSE (see text for 
details). (c) and (d) Axial views of the unmixed 3D reconstruction for CFSE and ATTO590 
respectively. 
The in-vivo experiments were performed by maintaining the CFSE concentration constant 
at 4μM and varying the ATTO590 concentration at 5μM, 10 μM and 15 μM. The pattern used 
for  in vivo  data acquisition was of 5x8 sources covering an area of 8x13mm
2. All 
measurements were performed in non-contact reflection geometry, reproducing the 
experimental conditions of most of our biologically relevant studies where superficial targets 
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subcutaneously in the upper torso area via two small incisions on the skin of the animal. The 
whole procedure was performed under terminal Isoflurane anesthesia. 
The in-vivo results are presented in Fig. 4 from which both qualitative and quantitative 
conclusions can be extracted. Figure 4a depicts the quantification results of the unmixing 
procedure performed in two ways: calculating the spectral strengths by (i) fitting the in situ 
collected spectra, represented by the open and solid squares for CFSE and ATTO590 
respectively (measured) and (ii) by using the known spectra obtained from a fluorimeter, 
represented by the open and solid down triangles for CFSE and ATTO590 (literature). Both 
data are fitted to a linear regression model with R
2 = 0.997 for case i and R
2 = 0.979 for case 
ii. The corresponding slopes are 1.21 for case (i) and 0.933 for case (ii). In order to visualize 
the increase in quantification accuracy obtained by spectral unmixing, Fig. 4b presents the 
ratios of the recovered concentrations of ATTO590 over CFSE for the measured  and 
literature  spectra cases (solid squares and open triangles, respectively), as well as the 
calculated known concentration ratios (solid circles), illustrating the improved accuracy that is 
achieved when measuring and fitting the spectra in situ. The ratios obtained with the 2D 
standard method (open circles) are off scale from the true calculated  ones and thus the 
corresponding data were not included in Fig. 4a. 
 
Fig. 4. (a) Quantification results for the recovered concentrations of ATTO590 and CFSE for 
the two methods of obtaining the spectral strengths (see text for details). (b) Ratios of the 
recovered concentrations of ATTO590 over CFSE (see text for details). 
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the in-vivo data is shown on a schematic outline of the mouse in Fig. 5. The images were 
obtained using the measured spectral fitting method described above. Figure 5a shows the 
reconstruction obtained with the raw data before the unmixing is performed, while Figs. 5b 
and 5c depict the unmixed 3D reconstructions of the two fluorophores clearly separated. 
 
Fig. 5. Coronal views of the 3D reconstructions of the CFSE and ATTO590 fluorescence signal 
overlaid on a schematic outline of the mouse. The inset shows the axial view of the same 
reconstructions. (a) the mixed reconstructions, (b) the unmixed ATTO590 reconstruction and 
(c) the unmixed CFSE reconstruction. 
5. Conclusions 
In conclusion, we have presented a method based on the combined and simultaneous 
collection of tomographic and spectral data which can be successfully applied to the 
separation of different fluorophores with overlapping signals. The capability of this system is 
very important when targeting different biological processes and monitoring cell population 
variations over time. The acquired spectral information could be furthermore used during the 
building of the weight matrix to provide a spectral constrain in the inversion algorithm 
resulting in a more robust reconstruction. The main advantage in the presented methodology is 
the acquisition of the fluorescence spectra in situ with the same device and under the same 
conditions as the fluorescence tomography data acquisition. This innovation can account for 
any spectral distortions due to the propagation of the fluorescence light through tissue with 
different optical properties and different pathlengths, thus improving significantly the 
localization of the object of interest at varying depths [34,35]. Furthermore, this feature could 
prove very important for accurate reconstruction and quantification in reflection geometry 
since autofluorescence could be accounted for as one additional fluorescence contributor and 
could then be efficiently subtracted [23]. Similar results have been obtained in transmission 
geometry as well, which is useful for applications where deep seated targets need to be 
investigated. 
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